A nurse‐led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study

Background Undiagnosed Type 2 diabetes (T2D) has been associated with advanced stage cancer at diagnosis, higher mortality, and lower long‐term all‐cause survival. This was a RCT pilot study to examine the feasibility of a nurse‐led T2D intervention for adults with newly diagnosed cancer (≤3 months)...

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 12; no. 11; pp. 12874 - 12880
Main Authors Scarton, Lisa, Nelson, Tarah, Jo, Ara, O’Neal, LaToya J., Yao, Yingwei, Huggins, Shavondra, Legaspi, Anatolia B., McClaren, Mariah J., Cabassa, Jake S., Burgos Melendez, Joan M., Munoz‐Pena, Juan M., Markham, Merry J., Murphy, Martina C., Chatzkel, Jonathan A., Rogers, Sherise, George, Thomas J.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.06.2023
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Undiagnosed Type 2 diabetes (T2D) has been associated with advanced stage cancer at diagnosis, higher mortality, and lower long‐term all‐cause survival. This was a RCT pilot study to examine the feasibility of a nurse‐led T2D intervention for adults with newly diagnosed cancer (≤3 months), and T2D, undiagnosed or untreated with medication, conducted at an outpatient oncology clinic affiliated with a large academic institution. Methods Participants needed to meet the eligibility criteria including a HbA1c level between 6.5% and 9.9%. Randomization was 1:1 to a 3‐month intervention that consisted of nursing‐led diabetes education and immediate initiation of metformin versus referral to primary care for usual care (control). Results Three hundred and seventy nine patients were screened using EHR, 55 agreed to participate, and 3 had eligible HbA1c levels and were randomized in the study. Primary reasons for study exclusion included life expectancy ≤2 years (16.9%), current use or inability to tolerate metformin (14.8%), and abnormal labs that contraindicated metformin use (13.9%). Conclusion This study was not feasible due to recruitment inefficiencies, but acceptable to all who qualified. Undiagnosed Type 2 diabetes (T2D) has been associated with advanced stage cancer at diagnosis, higher mortality, and lower long‐term all‐cause survival. This was a pilot RCT study to examine the feasibility of a nurse‐led T2D intervention for adults with newly diagnosed cancer (=3 months), and T2D, undiagnosed or untreated with medication, conducted at an outpatient oncology clinic affiliated with a large academic institution. This study was not feasible due to the cost, time, and personnel needed to screen participants with a point‐of‐care HbA1c test.
Bibliography:Lisa Scarton and Tarah Nelson should be considered joint first author.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.6118